The results of the ACTA trial show that new therapeutic regimens are of benefit in HIV-infected patients with cryptococcal meningitis. The findings were presented at the 9th IAS Conference on HIV Science held in Paris from 23 to 26 July 2017.
The study was conducted by Professor Thomas Harrison and his colleagues at St George's University of London, the Institut Pasteur in Paris, Paris Descartes University (Hôpital Necker-Enfants Malades), the ANRS site in Cameroon, and the MRC sites in Malawi, Tanzania, and Zambia.
Cryptococcal meningitis is a serious fungal infection frequent in immunosuppressed people, in particular AIDS patients. Despite increased use globally of antiretroviral treatment of people living with HIV, cryptococcal disease has not declined in incidence and accounts for over 180 000 deaths worldwide every year.
The new therapeutic regimens highlighted by the ACTA trial could potentially save over 80 000 lives a year. In the light of these findings, the WHO has just changed its guidelines for the management of cryptococcal disease and recommends 1-week induction treatment based on amphotericin B and flucytosine. If amphotericin is unavailable, high-dose fluconazole combined with oral flucytosine should be proposed. Olivier Lortholary and Charles Kouanfack, the investigators for the ANRS Cameroon site concluded that "These results will have a major impact on AIDS-related mortality in Africa. They show that flucytosine should rapidly be made available in resource-limited countries."